Highest-materiality recent filing
All 11 director nominees elected; Timothy M. Ring received 81.9M for, 12.0M against (lowest support).
Quest Diagnostics issues $500M of 5.000% senior notes due 2036
$500M aggregate principal, 5.000% coupon, maturity June 30, 2036.
Quest Diagnostics prices $500M of 5.000% senior notes due 2036
$500M aggregate principal of 5.000% senior notes due 2036 priced under shelf registration.
Quest Diagnostics Q1 revenue $2.90B (+9.2%), raises FY2026 EPS and revenue guidance
Reported diluted EPS $2.24 (+15.5%); adjusted diluted EPS $2.50 (+13.1%).
Quest Diagnostics elects former Walgreens CEO Timothy Wentworth to board
Elected Timothy Wentworth, former CEO of Walgreens Boots Alliance, as director effective March 9, 2026.
Quest Diagnostics Q4 rev $2.81B (+7.1%), adj EPS $2.42 (+8.5%); raises dividend 7.5%
FY2025 revenue $11.04B (+11.8%), reported EPS $8.75 (+13.8%), adjusted EPS $9.85 (+10.3%).
Quest Diagnostics presents at J.P. Morgan Healthcare Conference; no new financial details disclosed
Presentation at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84
Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.
Q2 revenue $2.76B, up 15.2% YoY; organic revenue growth 5.2%.
Quest Diagnostics 2025 meeting: all director nominees elected, exec comp approved
All 10 director nominees elected; highest vote for Robert B. Carter (94.2M for), lowest for Timothy M. Ring (87.2M for).
Quest Diagnostics Q1 revenue up 12.1% to $2.65B, raises FY reported EPS guidance
Q1 net revenues $2.65B (+12.1% YoY); reported diluted EPS $1.94 (+12.8%), adjusted diluted EPS $2.21 (+8.3%).
Long-term outlook: revenue CAGR 4-5%, adjusted EPS CAGR 7-9% beyond 2025.
CEO Jim Davis presented on driving sustainable growth and delivering long-term value.
Q4 revenue $2.62B (+14.5% YoY); reported diluted EPS $1.95 (+14.7%); adjusted diluted EPS $2.23 (+3.7%).
Quest Diagnostics Q3 revenue +8.5% to $2.49B, raises FY revenue guidance
Q3 revenue $2.49B (+8.5% YoY); reported EPS $1.99 (+1.5%); adjusted EPS $2.30 (+3.6%).
Quest Diagnostics closes LifeLabs acquisition; terms not disclosed
Acquisition of LifeLabs Inc., a Canadian lab diagnostics and digital health company, closed on August 26, 2024.
Quest Diagnostics prices $1.85B in senior notes to fund LifeLabs acquisition
Issued $400M at 4.600% due 2027, $600M at 4.625% due 2029, $850M at 5.000% due 2034.
Quest Diagnostics beats Q2 estimates, raises full-year guidance; announces four acquisitions
Q2 revenues $2.397B (+2.5% YoY); reported EPS $2.03 (-1% YoY), adjusted EPS $2.35 (+2.2% YoY)
Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35B (~US$985M)
Cash purchase price of ~C$1.35B (US$985M) including net debt, funded with cash and debt.
Quest Diagnostics shareholders approve officer exculpation, elect directors at annual meeting
Officer exculpation amendment approved with 80.2M for, 13.0M against; effective May 20, 2024.
Quest Diagnostics elects FedEx CIO Robert B. Carter to board; board now 10 members
Robert B. Carter, EVP and CIO of FedEx, elected to Quest's Board effective May 16, 2024.
Quest Diagnostics Q1 revenue $2.37B (+1.5% YoY); raises full-year adjusted EPS to $8.72-$8.97
Revenue $2.366B, up 1.5% YoY; base business revenue grew nearly 6%.
On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board.
Max materiality 0.85 · Median 0.62 · Most common event earnings